Drug delivery systems of gefitinib for improved cancer therapy: A review
Lung cancer is an uncontrolled and abnormal mass of growing cells with the highest mortality rate in the world. Progressive lung cancer shows a robust resistance to cancer therapy; today no acceptable therapeutic results are achieved with drugs. Gefitinib is an epidermal growth factor receptor tyros...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | OpenNano |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352952023000622 |
| _version_ | 1797630997934637056 |
|---|---|
| author | Deepak Nagdiya Manish Kumar Sanchit Arora Tania Bajaj Sima Kujur Prinsy Rana Arun Kumar Arti Singh Charan Singh |
| author_facet | Deepak Nagdiya Manish Kumar Sanchit Arora Tania Bajaj Sima Kujur Prinsy Rana Arun Kumar Arti Singh Charan Singh |
| author_sort | Deepak Nagdiya |
| collection | DOAJ |
| description | Lung cancer is an uncontrolled and abnormal mass of growing cells with the highest mortality rate in the world. Progressive lung cancer shows a robust resistance to cancer therapy; today no acceptable therapeutic results are achieved with drugs. Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor and blocks the proliferation of downstream signals that prevent cancer cells from proliferating by inhibiting tyrosine phosphorylation of the epidermal growth factor receptor. It also increases survival rates in patients with progressive lung cancer. Gefitinib belongs to the BCS class II drugs and due to its low bioavailability; its clinical use has been severely restricted. In recent years, several research papers have been published on the use of nanoparticles to increase therapeutic efficacy and drug targeting in lung cancer. Furthermore, to enhance the therapeutic efficacy of gefitinib, nanoparticles have been extensively studied and several nanoparticles including polymers, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nano cells, albumin, and silica nanoparticles have been developed for the treatment of lung cancer. All of these nanocarriers have improved targeted gefitinib treatment of lung cancer and improved nanomedicines for lung cancer treatment. This article provides an overview of various nanotechnology-based carrier systems of gefitinib such as polymeric, lipidic, albumin, and silica nanoparticles for lung cancer therapy. It also discusses the targeted and responsive delivery of gefitinib along with a combination strategy for better therapeutic efficacy. We believe that this manuscript will bring important information for formulation scientists to overcome the biopharmaceutical challenges associated with gefitinib for better clinical outcomes. |
| first_indexed | 2024-03-11T11:15:50Z |
| format | Article |
| id | doaj.art-d0a379df2ac04305bcc8f215289786a7 |
| institution | Directory Open Access Journal |
| issn | 2352-9520 |
| language | English |
| last_indexed | 2024-03-11T11:15:50Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | OpenNano |
| spelling | doaj.art-d0a379df2ac04305bcc8f215289786a72023-11-11T04:28:14ZengElsevierOpenNano2352-95202023-11-0114100183Drug delivery systems of gefitinib for improved cancer therapy: A reviewDeepak Nagdiya0Manish Kumar1Sanchit Arora2Tania Bajaj3Sima Kujur4Prinsy Rana5Arun Kumar6Arti Singh7Charan Singh8Department of Quality Assurance, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, IndiaDepartment of Pharmaceutics, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, IndiaDepartment of Pharmaceutics, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, IndiaDepartment of Pharmaceutics, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, India; IK Gujral Punjab Technical University, Kapurthala, Punjab, IndiaDepartment of Pharmaceutics, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, IndiaM.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala 133207, Haryana, IndiaDepartment of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya 824209, IndiaDepartment of Pharmacology, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, IndiaDepartment of Pharmaceutics, ISF College of Pharmacy, Affiliated to IK Gujral Punjab Technical University, Moga, Jalandhar, Punjab 142001, India; Department of Pharmaceutical Sciences, School of Sciences, Hemvati Nandan Bahuguna Garhwal University (A Central University), Srinagar, Uttarakhand 246174, India; Corresponding author.Lung cancer is an uncontrolled and abnormal mass of growing cells with the highest mortality rate in the world. Progressive lung cancer shows a robust resistance to cancer therapy; today no acceptable therapeutic results are achieved with drugs. Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor and blocks the proliferation of downstream signals that prevent cancer cells from proliferating by inhibiting tyrosine phosphorylation of the epidermal growth factor receptor. It also increases survival rates in patients with progressive lung cancer. Gefitinib belongs to the BCS class II drugs and due to its low bioavailability; its clinical use has been severely restricted. In recent years, several research papers have been published on the use of nanoparticles to increase therapeutic efficacy and drug targeting in lung cancer. Furthermore, to enhance the therapeutic efficacy of gefitinib, nanoparticles have been extensively studied and several nanoparticles including polymers, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nano cells, albumin, and silica nanoparticles have been developed for the treatment of lung cancer. All of these nanocarriers have improved targeted gefitinib treatment of lung cancer and improved nanomedicines for lung cancer treatment. This article provides an overview of various nanotechnology-based carrier systems of gefitinib such as polymeric, lipidic, albumin, and silica nanoparticles for lung cancer therapy. It also discusses the targeted and responsive delivery of gefitinib along with a combination strategy for better therapeutic efficacy. We believe that this manuscript will bring important information for formulation scientists to overcome the biopharmaceutical challenges associated with gefitinib for better clinical outcomes.http://www.sciencedirect.com/science/article/pii/S2352952023000622GefitinibLung cancerBioavailabilityNanomedicinesResistanceNanoparticles |
| spellingShingle | Deepak Nagdiya Manish Kumar Sanchit Arora Tania Bajaj Sima Kujur Prinsy Rana Arun Kumar Arti Singh Charan Singh Drug delivery systems of gefitinib for improved cancer therapy: A review OpenNano Gefitinib Lung cancer Bioavailability Nanomedicines Resistance Nanoparticles |
| title | Drug delivery systems of gefitinib for improved cancer therapy: A review |
| title_full | Drug delivery systems of gefitinib for improved cancer therapy: A review |
| title_fullStr | Drug delivery systems of gefitinib for improved cancer therapy: A review |
| title_full_unstemmed | Drug delivery systems of gefitinib for improved cancer therapy: A review |
| title_short | Drug delivery systems of gefitinib for improved cancer therapy: A review |
| title_sort | drug delivery systems of gefitinib for improved cancer therapy a review |
| topic | Gefitinib Lung cancer Bioavailability Nanomedicines Resistance Nanoparticles |
| url | http://www.sciencedirect.com/science/article/pii/S2352952023000622 |
| work_keys_str_mv | AT deepaknagdiya drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT manishkumar drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT sanchitarora drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT taniabajaj drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT simakujur drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT prinsyrana drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT arunkumar drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT artisingh drugdeliverysystemsofgefitinibforimprovedcancertherapyareview AT charansingh drugdeliverysystemsofgefitinibforimprovedcancertherapyareview |